All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
In its second deal of the week, Merck & Co. Inc. tapped Swiss firm Actelion Inc. for a potential $272 million agreement to develop new classes of renin inhibitors for cardio-renal diseases. (BioWorld Today)